Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in cancer survivors: a prospective observational cohort study

niversity of Manchester (UK)0 个研究点目标入组 4,439 人开始时间: 2014年3月19日最近更新: 2020年3月30日

适应症

试验速览

•1. Patients suitable for adjuvant radiotherapy* for cancer of the breast (invasive or in situ) including breast patients receiving neo-adjuvant chemotherapy
•2. Patients suitable for radical radiotherapy or brachytherapy for prostate cancer; including post-prostatectomy patients
•3. Patients suitable for radical radiotherapy, sequential or concurrent chemoradiotherapy or stereotactic body radiation therapy for lung cancer
•4. No other malignancy prior to treatment for the specified tumour types except basal cell or squamous cell carcinoma of the skin
•5. No evidence of distant metastases
•6. Patients able to provide a venous blood sample
•7. Willingness and ability to comply with scheduled visits, treatment plans and available for follow-up within country of origin
•8. Greater than 18 years of age; no upper age limit
•9. The capacity to understand the patient information sheet and the ability to provide written informed consent
•*Breast patients receiving chemotherapy should have completed their course of chemotherapy (anthracyclines) at least one month prior to radiotherapy commencing.

•1. Patients with metastatic disease
•2. Prior irradiation at the same site
•3. Planned use of protons
•4. Breast patients receiving concomitant chemo-radiation
•5. Male breast cancer patients
•6. Mastectomy patients
•7. Bilateral breast cancer
•8. Small cell lung cancer
•9. Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires
•10. Limited life expectancy due to co-morbidity
•11. Pregnant patients
•12. Partial breast irradiation
•13. Patients with breast implants if not removed during surgery
•14. Patients with known HIV infection/infectious hepatitis

发起方

niversity of Manchester (UK)